ESMO 2012 Press Release: Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer
Head-to-head study compares of crizotinib with standard chemotherapy in this patient group
- Date : 30 Sep 2012
- Topic : Lung and other thoracic tumours
VIENNA, Austria, 30 September 2012
The results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer, researchers said at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.
Rearrangements of the anaplastic lymphoma kinase (ALK) gene are found in about 5% of all lung cancers. In previous uncontrolled studies, crizotinib has been shown to induce significant clinical responses in patients with advanced ALK-positive lung cancer.
“This study is the first head-to-head comparison of crizotinib with standard chemotherapy in this patient group,” said lead study author Dr Alice Shaw from Massachusetts General Hospital Cancer Centre in Boston, USA. “In ALK-positive patients who have been previously treated with first-line, platinum-based chemotherapy, crizotinib is superior to standard single-agent chemotherapy in terms of response, progression-free survival and quality of life. These results establish crizotinib as the standard of care for patients with advanced, previously treated, ALK-positive lung cancer.”
The current global randomised phase III study compared the efficacy and safety of crizotinib with standard chemotherapy with pemetrexed or docetaxel, in 347 patients with ALK-positive lung cancer who had already been treated with chemotherapy.
The study showed that crizotinib prolonged progression-free survival to a median of 7.7 months compared to 3.0 months among those patients who received the chemotherapy (HR 0.49; 95% CI 0.37–0.64 ; P<0.0001). The overall response rate was also significantly higher in those treated with crizotinib (65% vs 20%; P<0.0001).
So far, the analysis of the overall survival rate with the two drugs is still immature, Dr Shaw said. That is, not enough events have occurred to draw meaningful conclusions.
“It is important to note that there was significant crossover in this study,” Dr Shaw said. “Patients who were randomised to receive chemotherapy and had disease progression were allowed to crossover to receive crizotinib. Hence, the majority of patients on the chemotherapy arm actually did receive crizotinib. This makes determination of overall survival benefit very challenging.”
In this study, certain side-effects were more frequent with crizotinib compared with single-agent chemotherapy. “However, despite this, patients still reported improved quality of life on crizotinib compared with chemotherapy,” Dr Shaw said.
Commenting on the data, Dr Enriqueta Felip, Head of the Lung Cancer Unit in Oncology Department at Vall d'Hebron University Hospital in Barcelona, Spain and chair of the ESMO 2012 Metastatic NSCLC track (not involved in the study) said: “The results of this study are of great clinical relevance. Crizotinib, an oral drug, is more effective than standard chemotherapy in previously treated lung cancer patients with a specific molecular alteration, ALK. This is the first randomised study in a group of lung cancer patients selected precisely because they have ALK-positive tumours. After the worldwide implementation of targeted therapy in lung cancer patients defined by another molecular alteration --EGFR mutation, this is the second group of lung cancer patients to clearly benefit from a therapy directly targeting a molecular alteration. The results of this study represent a significant step towards individualised therapy in lung cancer patients.”
Ganetespib in combination with docetaxel is well tolerated by patients with advanced non-small cell lung cancer
Results of the randomised Phase IIB/III Galaxy trial shows promising signals of activity in pre-specified patient populations. Commenting on the data, Dr Enriqueta Felip said: “The results of the GALAXY trial are potentially important because they may represent a new paradigm in the treatment of patients with lung cancer who no longer benefited from first-line chemotherapy. In this study comparing the standard second-line treatment, docetaxel, with docetaxel plus ganetespib the investigators stated that they found early signs of activity. The final results to be presented at the upcoming ESMO 2012 Congress will be of great interest.”
Disclaimer: Information contained in this press release was provided by the abstracts authors and reflects the content of the studies. It does not necessarily express ESMO's point of view.
Thank you for rating!
You have already rated this page, you can only rate it once!